Japan’s Takeda Pharmaceutical Company has collaborated with US-based biotechnology company HemoShear Therapeutics to discover and develop new therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH).

NASH is a serious, chronic liver disease characterised by inflammation and excessive fat accumulation in the liver, which may lead to fibrosis, cirrhosis, liver cancer and eventually liver failure.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the collaboration, Takeda will use HemoShear’s disease modelling platform REVEAL-Tx that applies principles of physiological blood flow to tissue derived from patients.

The latest platform enables drug candidates to be evaluated at human concentrations and offers significant insights into complex pathophysiological pathways by replicating human disease with precision.

Takeda GI Drug Discovery Unit head Dr Gareth Hicks said: “The ability to study pathophysiology in a human multi-cell system is crucial for our understanding of disease and how to develop best-in-class therapies.

“The ability to study pathophysiology in a human multi-cell system is crucial for our understanding of disease and how to develop best-in-class therapies.”

“We see the HemoShear platform as an integral component in our overall liver disease strategy that focuses on a ‘human first’ approach to the identification and validation of novel targets in NASH and other liver diseases.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the deal, HemoShear will receive upfront payments, and research and development funding, while Takeda will receive exclusive access to HemoShear’s disease modelling platform to discover and develop new therapeutics for specific liver diseases.

HemoShear will also be eligible to receive milestone payments of potentially $470m in addition to further royalties.

There is currently no available treatment for NASH and liver fibrosis that has been approved by the US Food and Drug Administration.

Image: Micrograph of non-alcoholic fatty liver disease (NAFLD). Photo: courtesy of Nephron via Wikipedia.